Navigation Links
Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
Date:10/1/2009

LAWRENCE, Mass., Oct. 1 /PRNewswire-FirstCall/ --NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that it has been recognized as the No. 3 Fastest Growing Company in Massachusetts by the Boston Business Journal. This is the third consecutive year that NxStage has been recognized by the Boston Business Journal as one of the fastest growing companies for its list, which this year ranks the "Fastest Growing Public Companies" by revenue growth from 2006 to 2008.

"We are pleased to be recognized by the Boston Business Journal for the rapid growth we have achieved as an innovative, market pioneer," said Jeffrey H. Burbank, Founder and Chief Executive Officer of NxStage Medical, Inc. "Our growth can be attributed, in part, to our continued efforts in developing the home hemodialysis market with the industry's only portable, easy-to-use home hemodialysis machine - the NxStage System One(TM), and our market share gains within the critical care market. We also further strengthened our revenue base through the strategic acquisition of Medisystems®, our in-center business, in late 2007."

The NxStage System One is the first truly portable hemodialysis system cleared for home use by the U.S. Food & Drug Administration. Its simplicity and compact size are intended to allow ease-of-use and to give patients the opportunity to travel with their therapy with their doctor's approval. It plugs into standard electrical outlets and, unlike conventional hemodialysis systems, requires no special infrastructure to operate. Under the guidance of their physician, patients can use the NxStage System One, with their trained partners, where, how and when it best meets their needs, at home or on vacation.

In 2009, NxStage broadened access to its dialysis products beyond the United States for the first time through a distribution agreement that brought the NxStage System One to the U.K. and Ireland. The Company also formed a strategic business alliance with Asahi Kasei Kuraray Medical, a leading medical supply company in Japan.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of end stage renal disease and acute kidney failure. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage's System One and other products, changes in market adoption of home daily hemodialysis, market adoption for the System One and other products internationally, and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2009. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

    Contact:
    Kristen K. Sheppard, Esq.
    VP, Investor Relations
    ksheppard@nxstage.com

SOURCE NxStage Medical, Inc.


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
2. The 60th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA -- Hynes Convention Center October 31 -- November 3, 2009
3. SPIRIT IV Results Reaffirm Strong Performance of Boston Scientific PROMUS(R) and TAXUS(R) Express(R) Stents
4. Boston Scientific Announces Schedule for European Society of Cardiology Congress
5. Boston Scientific Welcomes Results of Brain Aneurysm Clinical Trial
6. Boston Scientific Begins Clinical Trial for Next-Generation Nitinol Stent to Treat Iliac Artery Disease
7. Boston Scientific Launches Third-Generation Platinum Chromium Drug-Eluting Stent
8. Boston Scientific Data Show Real-World Survival Rates for Implantable Cardiac Device Patients Exceed Rates From Clinical Trials
9. Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientifics TAXUS(R) Liberte(R) Stent
10. Boston Scientific Welcomes Publication of HORIZONS AMI Trial Results in New England Journal of Medicine
11. Clinical Data Reinforce Safety and Efficacy of Boston Scientifics Two Drug- Eluting Stent Platforms
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... HILDEN , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt ... into a licensing and co-development agreement with Therawis Diagnostics GmbH ... project will be to develop and market PITX2 as a ... and other high-risk breast cancer patients. "We are ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
(Date:5/24/2016)... , May 24, 2016 ... den Markt gebracht, die es Ärzten erlaubt, ihre ... zu behandeln: MDLinking kombiniert Live Streaming mit einer ... Umfeld zu kommunizieren. Mediziner in Europa, Afrika, Asien ... sich bereits für die Plattform registriert. ...
Breaking Medicine Technology:
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... More than ... so it is not surprising that bariatric surgery has received increased attention in recent ... explains. Of course, when it comes to weight loss, most people are familiar with ...
(Date:5/27/2016)... ... May 27, 2016 , ... Two director-level employees of Horizon Blue Cross Blue ... Industry (TWIN) 2016 honorees. The award recognizes businesswomen who excel in their fields ... Director of the MLTSS (Managed Long-Term Services and Supports) Program at Horizon NJ Health ...
(Date:5/27/2016)... (PRWEB) , ... May 27, 2016 , ... An influential ... for a third time to shed lights on the variety of topics detailing why ... stories, “Nurse Appreciation” tackles why this career has gone from being in a major ...
(Date:5/27/2016)... New York, NY (PRWEB) , ... May 27, 2016 , ... ... the factors of a stroke, which we as a society can control and change. ... a stroke occurs nearly every 40 seconds within the United States. Plus, with an ...
(Date:5/27/2016)... ... May 27, 2016 , ... In response to ... who are unaware of the plight of aphasia. In collaboration with the American ... Awareness” campaign. , The link between stroke and aphasia is relatively unknown, but ...
Breaking Medicine News(10 mins):